Gujarat chemicals maker: pharma intermediates, semiconductor photoresist & battery electrolyte chemicals
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 32 | 36 | 36 | 37 | 41 | 41 | 41 |
| Reserves | 97 | 132 | 482 | 550 | 638 | 1.3k | 1.4k | 1.6k |
| Borrowings | 59 | 137 | 1 | 3 | 203 | 11 | 8 | 32 |
| Other Liabilities | 61 | 110 | 136 | 169 | 193 | 215 | 274 | 235 |
| Total Liabilities | 228 | 410 | 655 | 759 | 1.1k | 1.5k | 1.7k | 1.9k |
| AssetsFixed Assets | 62 | 161 | 178 | 222 | 357 | 499 | 700 | 601 |
| CWIP | 12 | 0 | 3 | 30 | 125 | 130 | 152 | 228 |
| Investments | 28 | 33 | 33 | 33 | 68 | 70 | 0 | 118 |
| Other Assets | 126 | 216 | 440 | 474 | 521 | 839 | 843 | 989 |
| Total Assets | 228 | 410 | 655 | 759 | 1.1k | 1.5k | 1.7k | 1.9k |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (64.6×) and current (69.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 60.3% growth and a 65× exit, ₹3246 only delivers your return if you pay ₹17,183. The price is currently baking in 19% growth.
EPS grows 60.3%/yr for 5 years, then fades to 6% over 2, exits at 65×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 60.3% | 75.45 |
| FY28 | 60.3% | 120.95 |
| FY29 | 60.3% | 193.89 |
| FY30 | 60.3% | 310.80 |
| FY31 | 60.3% | 498.21 |
| FY32 | 33.1% ·fade | 663.37 |
| FY33 | 6.0% ·fade | 703.17 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.